Pyxis Oncology Inc Cash Flow Conversion Efficiency
Pyxis Oncology Inc cash flow conversion efficiency. Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has a cash flow conversion efficiency ratio of -0.193x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.28 Million) by net assets ($68.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PYXS market cap for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Pyxis Oncology Inc (2019–2024)
Cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024. This chart illustrates how Pyxis Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pyxis Oncology Inc share price for real-time trading data and today's change.
Pyxis Oncology Inc Cash Flow Conversion Ratio Explained
Pyxis Oncology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pyxis Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pyxis Oncology Inc ranked by their cash flow conversion efficiency. Review PYXS free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Studentbostader I Sverige AB
ST:STUDBO
|
0.000x |
|
Engtex Group Bhd
KLSE:5056
|
0.094x |
|
PT Buana Artha Anugerah Tbk
JK:STAR
|
-0.003x |
|
HyVision System. Inc
KQ:126700
|
-0.033x |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
-0.014x |
|
Symphony Communication Public Company Limited
BK:SYMC
|
0.033x |
|
IBI Lion SOCIMI S.A.
MC:YIBI
|
0.006x |
|
Indomobil Multi Jasa Tbk
JK:IMJS
|
0.248x |
Annual Cash Flow Conversion Efficiency for Pyxis Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024. Also see Pyxis Oncology Inc total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $120.75 Million | $-57.67 Million | -0.478x | +15.09% |
| 2023-12-31 | $125.70 Million | $-70.71 Million | -0.563x | -1.26% |
| 2022-12-31 | $160.82 Million | $-89.33 Million | -0.555x | -310.90% |
| 2021-12-31 | $261.31 Million | $-35.33 Million | -0.135x | -120.97% |
| 2020-12-31 | $-15.64 Million | $-10.08 Million | 0.645x | -17.26% |
| 2019-12-31 | $-2.87 Million | $-2.24 Million | 0.779x | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more